Faculty

Institution

Unit

Venue

Jacqueline Vuky, M.D.

Associate Professor of Medicine

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Medicine

Department Of Pediatrics

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Division of Hematology & Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Department Of Medicine

Hematology and Medical Oncology

Department Of Pediatrics

Hematology and Oncology

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Jacqueline Vuky, M.D., is an Associate Professor of Medicine at Oregon Health & Science University. Her research focuses on clinical trials for genitourinary malignancies, particularly metastatic castration-resistant prostate cancer and muscle-invasive bladder cancer. She has led phase I/II trials investigating novel combinations, including enzalutamide with cabazitaxel and the first-in-human study of the CD46-targeting antibody-drug conjugate FOR46. Her recent work includes ctDNA-guided adjuvant atezolizumab in bladder cancer, published in the *New England Journal of Medicine*, and immunotherapy combinations for high tumor mutational burden solid tumors.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Jacqueline Vuky, M.D.

Oregon Health & Science University

Associate Professor of Medicine

You can click a keyword to filter the displayed items

oncology pharmacology cancer treatment urology cancer research pharmacotherapy clinical research cancer care medicinal research clinical trials anti-cancer agents cancer immunotherapy medicine radiation oncology prostate cancer drug trials clinical evidence therapeutic efficacy genitourinary cancers outcomes research surgical oncology therapeutic targets medical mycology cancer discovery drug targeting tumor targeting first-line pembrolizumab first-line therapy phase ii study molecular cancer gynecologic oncology cellular therapy cancer biology cancer management oncogenes cancer imaging field trial clinical therapeutics breast oncology prostatic disease prognostic biomarkers randomized controlled trials cisplatin-ineligible patients metastatic urothelial cancer phase ii trial advanced urothelial cancer advanced urothelial carcinoma post hoc analysis thoracic oncology cohort studies biomarker (medicine) long-term outcomes arrow trial advanced renal carcinoma nature clinical proteomics clinical nutrition phytotherapy research clinical pharmacology clinical implementation endocrine-related cancers non-operative treatment biomarker target anticoagulants dietary therapy benign prostatic hyperplasia preclinical drug evaluation treatment and prevention therapy resistance biomarker discovery drug development pharmaceutical research pan-cancer efficacy androgen receptor ar dependence phase 1 personalized medicine gynecology lung cancer cancer letter gynecologic cancers anatomical pathology surgical pathology carcinogenesis metastasis tumor biology medical sociology molecular diagnostics sarcoma histopathology bladder cancer tumor microenvironment medical history ovarian cancer urogynecology jama oncology breast cancer kidney cancer cancer cells mesothelioma translational research cervical cancer pathology

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Phase I/II Trial of Concurrent Chemo-Hormonal Enzalutamide and Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. The Oncologist (2026)

metastasiscancer carecancer treatmentprostate cancerprostatic diseasepharmacologyurologypharmacotherapyclinical trials

A0086 – a Randomised, Double-Blind Phase II Study of Autogene Cevumeran + Nivolumab (Nivo) vs. Nivo as Adjuvant Therapy for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma (Miuc). European Urology (2025)

Ctdna-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. New England Journal of Medicine (2025)

Efficacy and Safety of Pralsetinib in Ret Fusion-Positive Solid Tumors: Final Data From the Arrow Trial.. Journal of Clinical Oncology (2025)

Phase I, First-In-Human Study of For46 (Fg-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting Cd46, in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology (2025)

Rahul R. AggarwalJacqueline VukyDavid VanderWeeleMatthew RettigElisabeth I. HeathDavid QuigleyJiaoti HuangArun ChumberAlexander CheungAdam FoyeStanley LeungJill AbbeyAndrew DorrMarc NasoffJohn HunterSteven WangRobert R. FlavellLawrence FongBin LiuEric J. Small

tumor targetingfirst-in-human studydrug targetingcancer immunotherapyimmunologymedicinal researchcancer treatmentimmunotherapyprostate cancerimmune-modulating antibody-drug conjugatecancer researchcancer discoverypharmacologyclinical therapeuticsurologypharmacotherapyimmune checkpoint inhibitorsoncology

Data From Csf1R Inhibition in Patients With Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib. (2024)

Hans GelderblomAlbiruni A. RazakMatthew H. TaylorTodd M. BauerBreelyn WilkyJavier Martin-BrotoAlejandro F. GonzalezPiotr RutkowskiBartlomiej SzostakowskiThierry AlcindorRamy SalehSofia GentaSilvia StacchiottiMichiel van de SandeAndrew J. WagnerNicholas BernthalLara E. DavisJacqueline VukyChristopher TaitBahar MatinSupraja NarasimhanMaitreyi G. SharmaRodrigo Ruiz-SotoMatthew L. ShermanWilliam D. Tap

advanced solid tumorspharmacologytumor biology

Efficacy and Safety of Pembrolizumab in Patients With Advanced Urothelial Carcinoma Deemed Potentially Ineligible for Platinum‐Containing Chemotherapy: Post Hoc Analysis of Keynote‐052 and Leap‐011. Cancer (2024)

Peter H. O’DonnellYohann LoriotTibor CsosziNobuaki MatsubaraSang Joon ShinSe Hoon ParkVagif AtduevMahmut GumusSaziye Burcak KaracaPetros GrivasRonald de WitDaniel E. CastellanoThomas PowlesJacqueline VukyYujie ZhaoKaren O’HaraChinyere E. OkparaSonia FrancoBlanca Homet MorenoJakub ŻołnierekArlene O. Siefker‐Radtke

gliomasshort-term variabilitysurgical oncologypharmacologyvascular biologycancer immunotherapyreal world evidencecell biologytumor suppressorsadvanced urothelial carcinomamedicinal researchcellular therapyplatinum-containing chemotherapykey siteneurologymetastasisfull-scale measurementbrain tumor researchpost hoc analysismesotheliomaoncology

Randomized, Open-Label, Phase 2 Study of Nivolumab Plus Ipilimumab or Nivolumab Monotherapy in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden. Journal for ImmunoTherapy of Cancer (2024)

Michael SchenkerMauricio BurottoMartin RichardetTudor-Eliade CiuleanuAnthony GonçalvesNeeltje SteeghsPatrick SchoffskiPaolo A AsciertoMichele MaioIwona LugowskaLorena LupinacciAlexandra LearyJean-Pierre DelordJulieta GrasselliDavid S P TanJennifer FriedmannJacqueline VukyMarina TschaikaSomasekhar KonduruSai Vikram VemulaRuta SlepetisGeorgia KolliaMisena PaciusQuyen DuongNing HuangParul DoshiJonathan BadenMassimo Di Nicola

therapy resistancesurgical oncologycancer discoverypharmacologytherapeutic targetsthoracic oncologymetastatic solid tumorscancer immunotherapyimmunotherapypharmacotherapycancer treatmentradiation oncologymedicinal researchmetastasisrandomized controlled trialsnivolumab monotherapyoncologytreatment and preventionmedicinetherapeutic efficacy

1813P Phase I/II Trial of Oral Epi-7386 in Combination With Enzalutamide (Enz) Compared to Enz Alone in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Subjects: Current Phase I (Pi) Results. Annals of Oncology (2023)

A.L. LaccettiG. ChattaC. KyriakopoulosN. IannottiS.J. HotteM.C. MarkowskiR. PiliJ. VukyJ. ZhangF. SaadK. VillalunaB. YoungingerR. Le MoigneA. Cesano

cancer caretumor targetingrandomized controlled trialsanti-cancer agentsmedicinal researchsurgical oncologydrug trialsprostate cancerexcipientscancer researchpharmacologymedicineurologypharmacotherapyclinical trialsoncologyneuro-oncology

Concurrent Chemo-Hormonal Therapy of Enzalutamide (Enz) and Cabazitaxel (Cab) in Patients (Pts) With Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Final Analysis of Objective Response Rate (Orr), Radiographic Progression-Free Survival (Rpfs), and Overall Survival (Os).. Journal of Clinical Oncology (2023)

Alexandra SokolovaJulie N. GraffClaire E SmithTomasz M. BeerEmile LatourPetros GrivasMichael Thomas SchweizerCelestia S. HiganoJoshi J. AlumkalJacqueline VukyEvan Y. YuHeather H. Cheng

surgical oncologygenitourinary cancerspharmacologyconcurrent chemo-hormonal therapybenchmark studiesradiologycancer researchobjective response ratecancer treatmentpharmacotherapyprostate cancerurologycancer careclinical trialsradiation therapyfinal analysiscancer imagingclinical researchtherapeutic drug monitoringoncology

1
2
3
4
5
8
10 / page

Jacqueline Vuky, M.D.

Associate Professor of Medicine

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Medicine

Department Of Pediatrics

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Division of Hematology & Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Department Of Medicine

Hematology and Medical Oncology

Department Of Pediatrics

Hematology and Oncology

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Jacqueline Vuky, M.D.

Oregon Health & Science University

Associate Professor of Medicine

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Phase I/II Trial of Concurrent Chemo-Hormonal Enzalutamide and Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. The Oncologist (2026)

metastasiscancer carecancer treatmentprostate cancerprostatic diseasepharmacologyurologypharmacotherapyclinical trials

Ctdna-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. New England Journal of Medicine (2025)

Efficacy and Safety of Pralsetinib in Ret Fusion-Positive Solid Tumors: Final Data From the Arrow Trial.. Journal of Clinical Oncology (2025)

Data From Csf1R Inhibition in Patients With Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib. (2024)

advanced solid tumorspharmacologytumor biology

A.L. LaccettiG. ChattaC. KyriakopoulosN. IannottiS.J. HotteM.C. MarkowskiR. PiliJ. VukyJ. ZhangF. SaadK. VillalunaB. YoungingerR. Le MoigneA. Cesano

Alexandra SokolovaJulie N. GraffClaire E SmithTomasz M. BeerEmile LatourPetros GrivasMichael Thomas SchweizerCelestia S. HiganoJoshi J. AlumkalJacqueline VukyEvan Y. YuHeather H. Cheng

1
2
3
4
5
8
10 / page